Cellectis (CLLS) Earnings Date, Estimates & Call Transcripts $1.64 +0.05 (+3.14%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Cellectis Latest Earnings SummaryActual EPS (Nov. 4) -$0.23 Missed By -$0.03 Consensus EPS (Nov. 4) -$0.20 Cellectis announced Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.23, which missed analysts' consensus estimates of -$0.20 by $0.03. Quarterly revenue was reported to be $18.05 million, above the consensus estimate of $5 million. With a trailing EPS of -$1.30, Cellectis' earnings are expected to decrease next year, from ($0.46) to ($0.52) per share. Conference CallConference Call TranscriptPowered by Get Cellectis Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCLLS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CLLS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cellectis Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($0.46) EPSNext Year EPS Consensus Estimate: ($0.52) EPS Cellectis Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/4/2024Q3 2024-$0.20-$0.23 -$0.03-$0.23$5.00M$18.05M8/6/2024Q2 2024-$0.33-$0.28+$0.05-$0.28$6.00M$9.50M5/28/2024Q1 2024--$0.15 -$0.15-$0.15-$6.50M4/29/2024Q4 2023--$0.64 -$0.64-$0.64-$1.99M11/6/2023Q3 2023-$0.36-$0.31+$0.05-$0.31$4.03M$1.64M8/3/2023Q2 2023-$0.38-$0.14+$0.24-$0.09$7.80M$2.00M Get the Latest News and Ratings for CLLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. 5/4/2023Q1 2023-$0.30-$0.58 -$0.28-$0.58$9.30M$3.56M3/8/2023Q4 2022-$0.75-$0.57+$0.18-$0.55$20.48M$17.32M Cellectis Earnings - Frequently Asked Questions When did Cellectis announce their last quarterly earnings? Cellectis (NASDAQ:CLLS) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on CLLS's earnings history. Did Cellectis beat their earnings estimates last quarter? In the previous quarter, Cellectis (NASDAQ:CLLS) missed the analysts' consensus estimate of ($0.20) by $0.03 with a reported earnings per share (EPS) of ($0.23). Learn more on analysts' earnings estimate vs. CLLS's actual earnings. How can I listen to Cellectis's earnings conference call? The conference call for Cellectis's latest earnings report can be listened to online. Listen to Conference Call How can I read Cellectis's conference call transcript? The conference call transcript for Cellectis's latest earnings report can be read online. Read Transcript How much revenue does Cellectis generate each year? Cellectis (NASDAQ:CLLS) has a recorded annual revenue of $29.07 million. How much profit does Cellectis generate each year? Cellectis (NASDAQ:CLLS) has a recorded net income of -$101.06 million. CLLS has generated -$1.30 earnings per share over the last four quarters. What is Cellectis's EPS forecast for next year? Cellectis's earnings are expected to decrease from ($0.46) per share to ($0.52) per share in the next year. More Earnings Resources from MarketBeat Related Companies Cryoport Earnings Date Alvotech Earnings Date Neurogene Earnings Date biote Earnings Date Voyager Therapeutics Earnings Date Design Therapeutics Earnings Date Contineum Therapeutics Earnings Date Tango Therapeutics Earnings Date Acelyrin Earnings Date Canopy Growth Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. This page (NASDAQ:CLLS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
